ARTICLE | Tools & Techniques

Spark’s approach to the problem of redosing AAV gene therapies

June 2, 2020 11:30 PM UTC

Spark aims to solve one of the big problems plaguing gene therapy -- immune responses against viral vectors -- by adapting a strategy Hansa has been developing for transplant rejection.

Past infections with adenoviruses or adeno-associated viruses can lead to pre-existing antibodies against viral vectors that both pose a safety risk for gene therapy and dampen efficacy by reducing gene transfer. ...